Carcinoembryonic Antigen Market, By Gender, By Application, By End-user, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

Description

REPORT HIGHLIGHT

Carcinoembryonic Antigen Market size was valued at USD 2,215.5 Million in 2023, expanding at a CAGR of 6.50% from 2024 to 2032.

The endodermal epithelial cells of the embryo contain carcinoembryonic antigen (CEA). The fluids of the fetus, embryo, and gastrointestinal tract contain a glycoprotein called carcinoembryonic antigen. Carcinoembryonic antigen is also present in trace amounts in the blood, gastrointestinal cells, and colon mucosal cells. Additionally, the test can be used to diagnose and treat cancers like ovarian, lung, liver, colorectal, gastrointestinal, or colon cancers, as well as breast cancer. The market is expected to rise as a result of rising cancer incidence, an ageing population, and increased awareness. Over the past ten years, there has been a notable increase in the yearly number of cancer diagnoses worldwide. Additionally, as life expectancy rises, more people will receive a diagnosis during their lifetime, which will fuel market expansion.

Carcinoembryonic Antigen Market- Market Dynamics

Rising Incidence of Cancer

It is anticipated that the rising cases of cancer will fuel the market for carcinoembryonic antigens in the future. Uncontrolled development and spread of aberrant cells is a hallmark of cancer. Cancer is becoming common as a result of ageing populations, genetic predispositions, environmental pollutants, and lifestyle choices. The tumour marker carcinoembryonic antigen (CEA) is used to track the course of cancer and the efficacy of treatment. For instance, the World Health Organization (WHO), an intergovernmental agency based in the United States, stated in February 2024 that around 35 million new cases of cancer are expected to occur in 2050, a 77% increase from the 20 million cases forecast in 2022. Thus, the carcinoembryonic antigen market is expanding due to the increase in cancer incidence.

Carcinoembryonic Antigen Market- Key Insights

As per the analysis shared by our research analyst, the global Carcinoembryonic Antigen Market is estimated to grow annually at a CAGR of around 6.50% over the forecast period (2024-2032)

Based on gender segmentation, the male category was predicted to show the maximum market share in the year 2023

Based on application segmentation, the gastrointestinal cancer was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Carcinoembryonic Antigen Market- Segmentation Analysis:

The Global Carcinoembryonic Antigen Market is segmented on the basis of Gender, Application, End-user, and Region.

By application, the market is divided into Lung cancer, Gastrointestinal cancer (Colorectal cancer, Esophageal cancer, Liver cancer, Pancreatic cancer, Stomach cancer, Anal cancer, Gall bladder cancer), Breast cancer, Ovarian cancer, Prostate cancer, and Thyroid cancer. In 2023, the market was dominated by the gastrointestinal cancer category. Globally, colon, stomach, and pancreatic cancers are among the most common types of intestinal cancers. The need for efficient diagnostic and monitoring methods is fueled by their high prevalence and aggressive nature, with CEA acting as a crucial biomarker for these disorders. Furthermore, because the risk increases with age, the ageing population-especially in developed regions-contributes to the increased prevalence of gastrointestinal malignancies. The demand for CEA testing is further increased by this demographic trend, which further solidifies the gastrointestinal cancer segment's relevance.

The market for carcinoembryonic antigens is divided into end-user segments, including Hospitals, Oncology clinics, Diagnostic laboratories, Research centres and academic institutes. Revenue for the hospitals' segment in 2023 was. The main locations for cancer diagnosis, treatment, and surveillance are hospitals, where CEA testing is commonly used. Hospital usage of CEA tests is increasing as a result of the increased demand for monitoring and diagnostic tools due to the rising incidence of cancer worldwide. The accurate and effective use of CEA testing is further facilitated by hospitals' frequent access to trained staff and cutting-edge diagnostic tools. The focus on routine hospital monitoring and early detection of cancer patients contributes to the segment's growth.

Carcinoembryonic Antigen Market- Geographical Insights

Geographically, the Carcinoembryonic Antigen Market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

The market for carcinoembryonic antigen in North America is dominated worldwide due to the region's high cancer incidence, sophisticated healthcare system, and significant R&D expenditures. Due to the fact that early cancer identification and monitoring are essential for successful treatment, the market in this region is growing. In 2023, the American Cancer Society projected that 1.9 million new cases of cancer will be diagnosed in North America. CEA and other tumour markers are in high demand due to this high incidence rate. Furthermore, a number of major diagnostics companies, such as Abbott Laboratories and Roche Diagnostics, are based in North America and are constantly developing and broadening their product lines to meet this rising demand.

However, over the upcoming years, the carcinoembryonic antigen market in the Asia-Pacific region is expected to rise significantly due to factors such as rising cancer prevalence, rising healthcare costs, and increased awareness of early cancer detection. China, India, and Japan are at the forefront of this expansion because of their sizable populations and greater rates of cancer. In 2020, Asia accounted for around 49.3% of all cancer cases worldwide, as per the International Agency for Research on Cancer (IARC). Further driving market expansion in the area are government programs to enhance healthcare facilities and encourage early diagnostic testing, such as CEA.

Carcinoembryonic Antigen Market- Competitive Landscape:

The carcinoembryonic antigen market is driven by fierce competition between major firms, including Quest Diagnostics, Thermo Fisher Scientific Inc., Boster Biological Technology, Abcam Limited, Creative Diagnostics, and F. Hoffmann-La Roche Ltd, among others. These companies invest in R&D to improve the precision and affordability of carcinoembryonic antigen tests while utilizing their broad portfolios and robust distribution networks. Through advancements in immunoassays and point-of-care diagnostics, emerging businesses are also boosting the industry. Furthermore, technical developments and the growing emphasis on early cancer detection and monitoring are driving market demand and opening doors for both established and up-and-coming competitors. For instance, in December 2023, the global scientific development project for tusamitamab ravtansine is being halted by Sanofi. The Phase 3 CARMEN-LC03 trial, which evaluates tusamitamab ravtansine as a monotherapy in comparison to docetaxel in patients with metastatic non-squamous non-small cellular lung cancer (NSCLC) who have already received treatment, is the source of this decision.

Recent Developments:

April 2024: The renowned AI TechBio business and precision medicine pioneer Caris DiscoveryTM, the research arm of Caris Life Sciences(R) (Caris), announced a long-term strategic partnership with Merck KGaA, headquartered in Darmstadt, Germany. In the United States and Canada, Merck KGaA, which operates its healthcare business under the name EMD Serono, will partner with Caris DiscoveryTM to accelerate the search for and development of superior antibody-drug conjugates (ADC) for cancer patients.

March 2024: The FDA designated A2 Biotherapeutics Inc. as an orphan medication for A2B530, a new cell therapy designed to treat colorectal cancer in patients with germline heterozygous HLA-A02 positivity whose tumours express CEA but no longer express HLA-A02. This designation encourages the development of the medication. It provides incentives for progress in the treatment of colorectal cancer by highlighting its potential to address a major unmet need in this particular patient population.

July 2023: To determine the hepatitis C virus (HCV) antigen and antibody status simultaneously and independently from a single human plasma or blood sample, Roche Diagnostics India introduced the Elecsys HCV Duo, the country's first completely automated immunoassay. This innovative diagnostic technology simplifies the procedure for medical professionals and improves patient outcomes, representing a major advancement in HCV identification.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Boster Biological Technology
Abcam Limited
Creative Diagnostics
Aviva Systems Biology Corporation
AdvaCare Pharma
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Omega Diagnostics Ltd.
Medix Biochemica
RayBiotech, Inc.
Diazyme Laboratories Inc.
Quest Diagnostics Incorporated
Others

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY GENDER- MARKET ANALYSIS, 2019 - 2032

Male
Female

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

Lung cancer
Gastrointestinal cancer
Colorectal cancer
Esophageal cancer
Liver cancer
Pancreatic cancer
Stomach cancer
Anal cancer
Gall bladder cancer
Breast cancer
Ovarian cancer
Prostate cancer
Thyroid cancer

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Oncology clinics
Diagnostic laboratories
Research centres and academic institutes

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV4432

1. Carcinoembryonic Antigen Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Carcinoembryonic Antigen Market Snippet by Gender
- 2.1.2. Carcinoembryonic Antigen Market Snippet by Application
- 2.1.3. Carcinoembryonic Antigen Market Snippet by End-user
- 2.1.4. Carcinoembryonic Antigen Market Snippet by Country
- 2.1.5. Carcinoembryonic Antigen Market Snippet by Region
2.2. Competitive Insights

3. Carcinoembryonic Antigen Key Market Trends

3.1. Carcinoembryonic Antigen Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Carcinoembryonic Antigen Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Carcinoembryonic Antigen Market Opportunities
3.4. Carcinoembryonic Antigen Market Future Trends

4. Carcinoembryonic Antigen Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Carcinoembryonic Antigen Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Carcinoembryonic Antigen Market Landscape

6.1. Carcinoembryonic Antigen Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Carcinoembryonic Antigen Market - By Gender

7.1. Overview
- 7.1.1. Segment Share Analysis, By Gender, 2023 & 2032 (%)
- 7.1.2. Male
- 7.1.3. Female

8. Carcinoembryonic Antigen Market - By Application

8.1. Overview
- 8.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
- 8.1.2. Lung cancer
- 8.1.3. Gastrointestinal cancer
  - 8.1.3.1. Colorectal cancer
  - 8.1.3.2. Esophageal cancer
  - 8.1.3.3. Liver cancer
  - 8.1.3.4. Pancreatic cancer
  - 8.1.3.5. Stomach cancer
  - 8.1.3.6. Anal cancer
  - 8.1.3.7. Gall bladder cancer
- 8.1.4. Breast cancer
- 8.1.5. Ovarian cancer
- 8.1.6. Prostate cancer
- 8.1.7. Thyroid cancer

9. Carcinoembryonic Antigen Market - By End-user

9.1. Overview
- 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
- 9.1.2. Hospitals
- 9.1.3. Oncology clinics
- 9.1.4. Diagnostic laboratories
- 9.1.5. Research centres and academic institutes

10. Carcinoembryonic Antigen Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Carcinoembryonic Antigen Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Carcinoembryonic Antigen Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.8. France
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. France Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.3.8.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.9. Italy
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. Italy Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.3.9.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.10. Spain
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. United Kingdom Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.3.10.4. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.11. United Kingdom
  - 10.3.11.1. Overview
  - 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.3. United Kingdom Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.3.11.4. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.12. Russia
  - 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.2. Russia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.3.12.3. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.13. Netherlands
  - 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.2. Netherlands Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.3.13.3. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.14. Sweden
  - 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.2. Sweden Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.3.14.3. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.15. Poland
  - 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.2. Poland Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.3.15.3. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.3.16. Rest of Europe
  - 10.3.16.1. Overview
  - 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.16.3. Rest of the Europe Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.3.16.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Carcinoembryonic Antigen Key Manufacturers in Asia Pacific
- 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. Asia Pacific Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
- 10.4.5. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.7. India
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. India Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.4.7.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.8. China
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. China Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.4.8.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.9. South Korea
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. South Korea Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.4.9.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.10. Japan
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. Japan Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.4.10.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.12. Thailand
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Thailand Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.13. Indonesia
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Indonesia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.5. Latin America
- 10.5.1. Overview
- 10.5.2. Carcinoembryonic Antigen Key Manufacturers in Latin America
- 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. Latin America Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
- 10.5.5. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
- 10.6.1. Overview
- 10.6.2. Carcinoembryonic Antigen Key Manufacturers in Middle East and Africa
- 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. Middle East and Africa Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
- 10.6.5. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.8. United Arab Emirates
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. United Arab Emirates Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.6.8.4. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Carcinoembryonic Antigen Industry

11.1. Competitive Dashboard
11.2. Company Profiles
- 11.2.1. Boster Biological Technology
- 11.2.2. Abcam Limited
- 11.2.3. Creative Diagnostics
- 11.2.4. Aviva Systems Biology Corporation
- 11.2.5. AdvaCare Pharma
- 11.2.6. F. Hoffmann-La Roche Ltd.
- 11.2.7. Thermo Fisher Scientific Inc.
- 11.2.8. Omega Diagnostics Ltd.
- 11.2.9. Medix Biochemica
- 11.2.10. RayBiotech, Inc.
- 11.2.11. Diazyme Laboratories Inc.
- 11.2.12. Quest Diagnostics Incorporated
- 11.2.13. Others

12. 360 Degree Analyst View

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us